Entyvio®

Understanding Entyvio® 

Entyvio® (vedolizumab) is a biologic medication used to treat inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). It is an integrin receptor antagonist that specifically targets the gut, reducing inflammation without suppressing the entire immune system. Entyvio® is commonly prescribed for patients who need long-term management of IBD and prefer a gut-focused therapy rather than broad immunosuppression. It helps reduce symptoms, promote remission, and improve quality of life for individuals with moderate to severe UC or CD.

How Entyvio® Works:

• Blocks integrin receptors to prevent immune cells from causing gut inflammation.
• Targets the digestive tract, avoiding widespread immune suppression.
• Helps achieve and maintain remission in ulcerative colitis and Crohn’s disease.

FDA Approval:

• 2014 – Approved for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD)

For more information, please visit the Entyvio® patient website and speak with your healthcare provider to determine if Entyvio® is the right treatment option for you.